3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

Coelho, Luiz Gonzaga Vaz; Maguinilk, Ismael; Zaterka, Schlioma; Parente, José Miguel Luz; Passos, Maria do Carmo Friche; Moraes-Filho, Joaquim Prado P

doi:10.1590/s0004-28032013005000001

Cited by 32 publications

(40 citation statements)

References 201 publications

(227 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In developing countries, there is a high prevalence of primary and secondary resistance to metronidazole and also to levofloxacin is present, and the bismuth compounds are very difficult to achieve. To overcome these limitations, furazolidone-based treatments have been suggested in developing countries by the World Gastroenterology Organization and Latin-America guidelines [2,12,13]. On the other hand, the low rate of primary H. pylori resistance toward furazolidone in developed countries may render appealing the use of this drug also in these geographic areas [14,15].…”

Section: Resultsmentioning

confidence: 99%

Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not?

Rizzuto¹,

Pasqualucci²,

Chehter³

2014

GHOA

View full text Add to dashboard Cite

a. Past or present duodenal and/or gastric ulcer, with or without complications. b. Following resection of gastric cancer. AbstractObjective: To analyze eradication rate and evaluate collateral effects of an existing alternative dosage, comprised of Omeprazole, tetracycline and furazolidone for 7 days in patients with gastric and/or duodenal ulcers and first-degree relatives of family members with a diagnosis of gastric cancer with positive study for Helicobacter pylori (H. pylori) and treatment-naive. Design and location:The out patients from the Clinic of the Gastroenterology Department of the ABC Medical School, Santo Andre, SP-Brazil. Results: 85 patients were included in the study of which 55 completed the treatment. 95% of the patients had an adequate adherence to the treatment. 49% of the patients analyzed by protocol had at least one side effect, with the most common being nausea (24%) and there was no statistical difference between the relation of side effects and lapse of treatment for H. pylori. 5% (3 patients) interrupted the treatment. The eradication rate per protocol (PP) was 96% (95%CI: 84% to 100%) for patients who completed the treatment. Patients and methods: Conclusion:The therapy based on Omeprazole, tetracycline and furazolidone in the dosages proposed represents a good and low-cost alternative to the first-line therapy to eradicate infection by H. pylori in treatment-naive patients in a developing country.

show abstract

Section: Resultsmentioning

confidence: 99%

Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not?

Rizzuto¹,

Pasqualucci²,

Chehter³

2014

GHOA

View full text Add to dashboard Cite

show abstract

“…In Brazil, commercial capsule of 13 C-urea is not available, hindering the incorporation of this test to the daily gastroenterology practice (6) . The Pharmacy Division of our Institution may formulate capsule of 13 C-urea, and provide for the patients of our Hospital to undergo urea breath test.…”

Section: Discussionmentioning

confidence: 99%

“…Capsule based 13 C-urea breath test has been reported with lower dose than the conventional test with high sensitivity and specificity, avoiding bacterial oral flora interference, and in a shorter time (7,25,27,28) . One of the limitations for 13 C-urea breath test to be incorporated into daily gastroenterology practice in Brazil is the substrate ( 13 C-urea) acquisition in capsule presentation (6) . Thus, the purpose of this study was to evaluate the usefulness of a capsule-based 13 C-urea, manipulated by the Pharmacy Division of a Tertiary Care Hospital for the clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Low Dose Capsule Based 13c-Urea Breath Test Compared With the Conventional 13c-Urea Breath Test and Invasive Tests

Mattar

Villares

Marostegam

et al. 2014

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Context-One of the limitations of 13 C-urea breath test for Helicobacter pylori infection diagnosis in Brazil is the substrate acquisition in capsule presentation. Objectives-The purpose of this study was to evaluate a capsule-based 13 C-urea, manipulated by the Pharmacy Division, for the clinical practice. Methods-Fifty patients underwent the conventional and the capsule breath test. Samples were collected at the baseline and after 10, 20 and 30 minutes of 13 C-urea ingestion. Urease and histology were used as gold standard in 83 patients. Results-In a total of 50 patients, 17 were positive with the conventional 13 C-urea (75 mg) breath test at 10, 20 and 30 minutes. When these patients repeated breath test with capsule (50 mg), 17 were positive at 20 minutes and 15 at 10 and 30 minutes. The relative sensitivity of 13 C-urea with capsule was 100% at 20 minutes and 88.24% at 10 and at 30 minutes. The relative specificity was 100% at all time intervals. Among 83 patients that underwent capsule breath test and endoscopy the capsule breath test presented 100% of sensitivity and specificity. Conclusion-Capsule based breath test with 50 mg 13 C-urea at twenty minutes was found highly sensitive and specific for the clinical setting. HEADINGS-Helicobacter pylori. Breath Test. Urea, analysis.

show abstract

“…It is known that chronic gastritis caused by this infection may lead to atrophic gastritis, intestinal metaplasia and dysplasia, thus setting the role of H. pylori in gastric carcinogenesis cascade (4,7) . Therefore recent meetings on the subject suggest to eradicate this organism in all infected individuals (2,3,8) . The most widely used treatment consists of an association of clarithomycin, amoxyllin and a proton pump inhibitor (PPI) during 7 days (3,8) .…”

mentioning

confidence: 99%

“…Therefore recent meetings on the subject suggest to eradicate this organism in all infected individuals (2,3,8) . The most widely used treatment consists of an association of clarithomycin, amoxyllin and a proton pump inhibitor (PPI) during 7 days (3,8) . However, it is noticed that the currently used treatments in order to eradicate H. pylori present decreasing levels of success.…”

mentioning

confidence: 99%